Crescent Biopharma (CBIO) Shares Outstanding (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Shares Outstanding (Entity) of $7.2 million for Q2 2026, up 67.98% year-over-year from $4.3 million in Q2 2025, and up 3.28% quarter-over-quarter from $7.0 million in Q1 2026.
Crescent Biopharma (CBIO) Shares Outstanding (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Shares Outstanding (Entity) for 14 consecutive years, with $7.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Shares Outstanding (Entity) rose 67.98% year-over-year to $7.2 million; the TTM figure through Jun 2026 stood at $7.2 million (up 67.98% YoY), while the FY2025 annual figure was $7.0 million, up 987.08% from the prior year.
- Shares Outstanding (Entity) grew to $7.2 million in Q2 2026 per CBIO's latest filing, from $7.0 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $7.2 million in Q2 2026 and bottomed at $523924.0 in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $2.1 million across 5 years, with a median of $644674.0 in 2024.
- On a YoY basis, Shares Outstanding (Entity) climbed as much as 987.08% in 2025 and fell as far as 0.13% in 2025.
- Crescent Biopharma's Shares Outstanding (Entity) stood at $543778.0 in 2022, then advanced by 18.42% to $643937.0 in 2023, then advanced by 0.14% to $644840.0 in 2024, then soared by 987.08% to $7.0 million in 2025, then climbed by 3.18% to $7.2 million in 2026.
- Business Quant data shows CBIO's Shares Outstanding (Entity) at $7.2 million in Q2 2026, $7.0 million in Q1 2026, and $7.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 133.61 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 217.35 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 445.06 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 241.70 Mn |
| 10 | Crescent Biopharma | 1.05 Bn | 875.92 Mn | - | 64.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.23 Mn |
| Mar 31, 2026 | 7.00 Mn |
| Dec 31, 2025 | 7.01 Mn |
| Sep 30, 2025 | 4.63 Mn |
| Jun 30, 2025 | 4.31 Mn |
| Mar 31, 2025 | 645,223.00 |
| Dec 31, 2024 | 644,772.00 |
| Sep 30, 2024 | 644,840.00 |
| Jun 30, 2024 | 644,838.00 |
| Mar 31, 2024 | 644,572.00 |
| Dec 31, 2023 | 633,425.00 |
| Sep 30, 2023 | 643,497.00 |
| Jun 30, 2023 | 642,762.00 |
| Mar 31, 2023 | 603,501.00 |
| Dec 31, 2022 | 525,312.00 |
| Sep 30, 2022 | 524,239.00 |
| Jun 30, 2022 | 524,073.00 |
| Mar 31, 2022 | 523,314.00 |
| Dec 31, 2021 | 514,532.00 |
| Sep 30, 2021 | 515,647.00 |